TY  - JOUR 
AU  - García Campelo, María del Rosario
AU  - Zhou, C.
AU  - Ramalingam, S.S.
AU  - Lin, H.M.
AU  - Kim, T.M.
AU  - Riely, G.J.
AU  - Mekhail, T.
AU  - Nguyen, D.
AU  - Goodman, E.
AU  - Mehta, M.
AU  - Popat, S.
AU  - Jänne, P.A.
PY  - 2023
SN  - 2077-0383
UR  - http://hdl.handle.net/20.500.11940/21829
AB  - Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in adults with previously treated EGFR ex20ins+ metastatic non-small...
LA  - eng
TI  - Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
DO  - 10.3390/jcm12010112
T2  - Journal of Clinical Medicine
KW  - AS A Coruña
KW  - CHUAC
VL  - 12
ER  -